Phase 4 trial in 221 UK infants: 4CMenB at 8 and 12 weeks v 8 and 16 weeks gave similar protective hSBA titre rates 4 weeks post-primary for all strains (eg PorA 64% v 75%, NS), but lower titres; the reduced-interval schedule caused less irritability and crying.
RCTn = 221 infants
Thorn et al. Immunogenicity, reactogenicity, and safety of a reduced-interval 4CMenB primary immunisation schedule in UK infants: a multicentre, open-label, assessor-blinded, phase 4 randomised controlled trial